Liquidia Provides Update on Clinical Pipeline Targeting PAH and PH-ILD
Enrolled first PH-ILD patient in the open-label ASCENT study of YUTREPIA Confirmed with FDA that a single pivotal efficacy trial […]
Iris Energy Announces Monthly Investor Update for December 2023
10 EH/s expansion fully fundedConstruction ahead of schedule SYDNEY, Australia, Jan. 05, 2024 (GLOBE NEWSWIRE) — Iris Energy Limited (NASDAQ: […]
Kymera Therapeutics Announces Pricing of $275 Million Public Offering
WATERTOWN, Mass., Jan. 05, 2024 (GLOBE NEWSWIRE) — Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new […]
Bionomics to Present at Biotech Showcase™ 2024
ADELAIDE, Australia and CAMBRIDGE, Mass., Jan. 05, 2024 (GLOBE NEWSWIRE) — Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage […]
AR Exhibition “Ragnarok Real World Experience” to Open in Thailand
Seoul, Jan. 05, 2024 (GLOBE NEWSWIRE) — – GRAVITY Co., Ltd. (NasdaqGM: GRVY) (“Gravity” or “Company”), a developer and publisher […]
17EdTech Has Regained Compliance with Nasdaq’s Minimum Bid Price Requirement
BEIJING, Jan. 05, 2024 (GLOBE NEWSWIRE) — 17 Education & Technology Group Inc. (Nasdaq: YQ) (“17EdTech” or the “Company”), a […]
WISeKey and Cybersecurity Tech Accord to Host an Influential Roundtable Discussion During Davos 2024 Event
The Roundtable “AI Unleashed – Ensuring Safety and Leveraging Decentralization” Will Take Place on January 17, 2024 in Davos, Switzerland […]
AirNet Announces Receipt of Deficiency Letter from Nasdaq
BEIJING, Jan. 05, 2024 (GLOBE NEWSWIRE) — AirNet Technology Inc., formerly known as AirMedia Group Inc. (the “Company”) (Nasdaq: ANTE), […]
OPKO Health Announces Pricing of Private Offering of $200 Million Convertible Senior Notes Due 2029
MIAMI, Jan. 04, 2024 (GLOBE NEWSWIRE) — OPKO Health, Inc. (NASDAQ: OPK) (the “Company”) today announced the pricing of its […]
Dyne Therapeutics Announces Pricing of $300 Million Public Offering of Common Stock
WALTHAM, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) — Dyne Therapeutics, Inc. (Nasdaq:DYN), a clinical-stage muscle disease company focused on advancing innovative […]
